MX347883B - Anticuerpo monoclonal ds6, antigeno ca6 asociado con tumor, y metodos de uso de los mismos. - Google Patents

Anticuerpo monoclonal ds6, antigeno ca6 asociado con tumor, y metodos de uso de los mismos.

Info

Publication number
MX347883B
MX347883B MX2013004010A MX2013004010A MX347883B MX 347883 B MX347883 B MX 347883B MX 2013004010 A MX2013004010 A MX 2013004010A MX 2013004010 A MX2013004010 A MX 2013004010A MX 347883 B MX347883 B MX 347883B
Authority
MX
Mexico
Prior art keywords
methods
monoclonal
tumor
monoclonal antibody
associated antigen
Prior art date
Application number
MX2013004010A
Other languages
English (en)
Inventor
Anne Elizabeth Wennerberg
Diane A Semer
Original Assignee
East Carolina Univ *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by East Carolina Univ * filed Critical East Carolina Univ *
Publication of MX347883B publication Critical patent/MX347883B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un anticuerpo monoclonal seleccionado del grupo que consiste de anticuerpo DS6 monoclonal, anticuerpos monoclonales que específicamente se unen al enlace de epítope o de antígeno a través de anticuerpo DS6 monoclonal, y fragmentos de lo anterior que específicamente se unen al enlace de antígeno epítope, a través de anticuerpo DS6 monoclonal; los métodos de uso de tales anticuerpos y el antígeno aislado, unido a través de los anticuerpos, también se describen.
MX2013004010A 2000-08-18 2001-08-17 Anticuerpo monoclonal ds6, antigeno ca6 asociado con tumor, y metodos de uso de los mismos. MX347883B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/641,499 US6596503B1 (en) 2000-08-18 2000-08-18 Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
PCT/US2001/041765 WO2002016401A2 (en) 2000-08-18 2001-08-17 Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof

Publications (1)

Publication Number Publication Date
MX347883B true MX347883B (es) 2017-05-16

Family

ID=24572648

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013004010A MX347883B (es) 2000-08-18 2001-08-17 Anticuerpo monoclonal ds6, antigeno ca6 asociado con tumor, y metodos de uso de los mismos.
MXPA03001460A MXPA03001460A (es) 2000-08-18 2001-08-17 Anticuerpo monoclonal ds6, antigeno ca6 asociado con tumor, y metodos de uso de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MXPA03001460A MXPA03001460A (es) 2000-08-18 2001-08-17 Anticuerpo monoclonal ds6, antigeno ca6 asociado con tumor, y metodos de uso de los mismos.

Country Status (7)

Country Link
US (5) US6596503B1 (es)
EP (1) EP1362060A4 (es)
AU (1) AU2001289145A1 (es)
CA (1) CA2419270C (es)
GB (1) GB2383331B (es)
MX (2) MX347883B (es)
WO (1) WO2002016401A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX342007B (es) 2003-05-14 2016-09-09 Immunogen Inc Composicion de farmaco conjugado.
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7834155B2 (en) * 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
MXPA06000830A (es) * 2003-07-21 2006-04-18 Immunogen Inc Un conjugado citotoxico ca6 antigeno-especifico y metodos para utilizar el mismo.
AU2012201260B2 (en) * 2003-07-21 2014-10-23 Immunogen, Inc. A CA6 antigen-specific cytotoxic conjugate and methods of using the same
EP1732596A2 (en) * 2004-03-11 2006-12-20 Shantha West, Inc. Therapeutic use of rm1 antigen
JP5165387B2 (ja) 2005-02-11 2013-03-21 イムノゲン インコーポレーティッド 安定な薬物複合体を調製するための方法
MX336033B (es) 2005-08-03 2016-01-07 Immunogen Inc Formulaciones de inmunoconjugado.
JP2009504193A (ja) * 2005-08-22 2009-02-05 イミュノジェン・インコーポレーテッド Ｃａ６抗原特異的細胞傷害性コンジュゲート、および該コンジュゲートを用いる方法
CN104804094A (zh) * 2005-08-22 2015-07-29 伊缪诺金公司 Ca6抗原特异性细胞毒性偶联物及其应用方法
CN102989000B (zh) 2005-08-24 2016-04-20 伊缪诺金公司 制备美登木素生物碱抗体缀合物的方法
US20070248539A1 (en) * 2006-04-24 2007-10-25 Shantha West Inc. AgRM2 antigen
AU2007355108B2 (en) 2006-11-27 2013-07-11 Patrys Limited Novel glycosylated peptide target in neoplastic cells
US8012678B2 (en) * 2007-07-24 2011-09-06 Wisconsin Alumni Research Foundation Biomarkers for human papilloma virus-associated cancer
DK2281006T3 (da) 2008-04-30 2017-11-06 Immunogen Inc Tværbindingsmidler og anvendelser deraf
ES2595362T3 (es) 2008-06-16 2016-12-29 Patrys Limited Anticuerpos LM, fragmentos funcionales, antígeno diana LM-1 y métodos para prepararlos y usarlos
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
JP5701212B2 (ja) * 2008-09-09 2015-04-15 ソマロジック・インコーポレーテッド 肺癌バイオマーカーとその使用
WO2010126551A1 (en) 2009-04-30 2010-11-04 Immunogen, Inc. Potent conjugates and hydrophilic linkers
HUE043645T2 (hu) 2009-06-03 2019-08-28 Immunogen Inc Konjugációs módszerek
MX2012014268A (es) * 2010-07-09 2013-02-12 Somalogic Inc Biomarcadores de cancer de pulmon y usos de los mismos.
CA2804857C (en) 2010-08-13 2021-07-06 Somalogic, Inc. Pancreatic cancer biomarkers and uses thereof
KR20230128583A (ko) 2011-03-29 2023-09-05 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
MY171008A (en) 2011-03-29 2019-09-23 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process
MX355416B (es) * 2011-10-24 2018-04-18 Somalogic Inc Biomarcadores de cancer de pulmon y usos de los mismos.
EP2771351B1 (en) 2011-10-28 2017-06-14 Patrys Limited Pat-lm1 epitopes and methods for using same
JP2012161321A (ja) * 2012-03-30 2012-08-30 Immunogen Inc Ｃａ６抗原特異的細胞傷害性コンジュゲート、および該コンジュゲートを用いる方法
SG10201702737TA (en) 2012-10-04 2017-05-30 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
US9989524B2 (en) * 2013-02-05 2018-06-05 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
US9844607B2 (en) 2013-02-05 2017-12-19 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
EP3220959A1 (en) 2014-11-19 2017-09-27 ImmunoGen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
AU2017213858A1 (en) 2016-02-05 2018-08-16 Immunogen, Inc. Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
WO2017194568A1 (en) 2016-05-11 2017-11-16 Sanofi Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931385A (en) * 1985-06-24 1990-06-05 Hygeia Sciences, Incorporated Enzyme immunoassays and immunologic reagents
US5366866A (en) 1991-07-25 1994-11-22 Duke University Method of diagnosing ovarian and endometrial cancer with monoclonal antibodies OXA and OXB
WO1994021293A1 (en) 1993-03-19 1994-09-29 Duke University Method of treatment of tumors with an antibody binding to tenascin
WO1994021294A1 (en) 1993-03-19 1994-09-29 Bigner Darell D Method of treating tumors with antibodies
US5871941A (en) 1995-07-28 1999-02-16 Univ British Columbia Method of testing expression of CA125 antigen in cultured ovarian surface epithelial cells to identify and monitor individuals having a predisposition to develop ovarian cancer
US7037667B1 (en) * 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
MXPA06000830A (es) 2003-07-21 2006-04-18 Immunogen Inc Un conjugado citotoxico ca6 antigeno-especifico y metodos para utilizar el mismo.
US7834155B2 (en) 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same

Also Published As

Publication number Publication date
EP1362060A4 (en) 2004-09-08
US20030215895A1 (en) 2003-11-20
US8728741B2 (en) 2014-05-20
GB2383331B (en) 2004-09-29
US20090155930A1 (en) 2009-06-18
US20120045776A1 (en) 2012-02-23
WO2002016401A2 (en) 2002-02-28
GB0306083D0 (en) 2003-04-23
EP1362060A2 (en) 2003-11-19
WO2002016401A3 (en) 2002-04-11
US8067186B2 (en) 2011-11-29
US20070196276A1 (en) 2007-08-23
GB2383331A (en) 2003-06-25
AU2001289145A1 (en) 2002-03-04
US7507410B2 (en) 2009-03-24
MXPA03001460A (es) 2004-12-13
US6596503B1 (en) 2003-07-22
US7351805B2 (en) 2008-04-01
CA2419270A1 (en) 2002-02-28
CA2419270C (en) 2013-05-14

Similar Documents

Publication Publication Date Title
MX347883B (es) Anticuerpo monoclonal ds6, antigeno ca6 asociado con tumor, y metodos de uso de los mismos.
MX2021015880A (es) Fragmentos de unión al antígeno cd3 y composiciones que comprenden los mismos.
CR20200579A (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
EA201401134A1 (ru) Hla-рестиктированные пептидоспецифические антигенсвязывающие белки
WO2016154047A3 (en) Monoclonal antigen-binding proteins to intracellular oncogene products
FI963033A0 (fi) Tuumorirejektioantigeenin esiasteeseen MAGE-1 sitoutuvia monoklonaalisia vasta-aineita, rekombinantti-MAGE-1 ja MAGE-1-peräisiä immunogeenisia peptidejä
WO1997046589A3 (en) Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
IL148113A0 (en) Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
ES2184660T1 (es) Anticuerpos humanizados que secuestran peptidos abeta.
MX421450B (es) Composiciones y metodos relacionados con conjugados de farmacos de anticuerpo anti grupo de diferenciacion 19 (cd19)
EP2301968A3 (en) Humanized monoclonal antibody HPAM4
MX349009B (es) Anticuerpos contra el receptor del factor de crecimiento similar a insulina.
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
PE20071055A1 (es) Anticuerpos anti mn
BRPI0607486A2 (pt) anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos
WO2003034903A3 (en) Psma antibodies and protein multimers
MX2024010593A (es) Anticuerpos 3e10 humanizados, variantes y fragmento de unión al antígeno de los mismos
DE60224346D1 (de) Monoklonales Antikörper gegen das HCV Kernantigen
WO2008098917A3 (en) Novel antibodies against igf-ir
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
WO2003087340A3 (en) Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
CY1115295T1 (el) Συνθεση για την θεραπεια παθολογιας συνδεομενης με msrv/herv-w
EA201000053A1 (ru) Новые антитела